The herpes simplex virus thymidine kinase ( HSV -tk ) gene conferring ganciclovir ( GCV ) -specific sensitivity to transduced cells might control Graft -versus -Leukemia ( GvL ) / Graft -versus -Host Disease ( GvHD ). Human T lymphocytes were engineered with an LSN -tk retroviral vector encoding tk and neomycin resistance ( NeoR ) genes. A total of 80Â10 6 tk + lymphocytes were injected intraperitoneally in NOD -SCID mice. Engraftment was evaluated by human CD45 + / CD3 + cytofluorimetric analysis and NeoRbased polymerase chain reaction ( PCR ) on peripheral blood, bone marrow, liver, thymus, and spleen on day + 5. After 14 days, GCV ( 10 mg / kg daily ) cytofluorimetric analysis and PCR were repeated ( day + 19 ). Immunohistological studies with anti -CD3 monoclonal antibody followed by alkaline phosphatase and monoclonal anti -alkaline phosphatase staining were performed on spleen and liver at the same time points. Human CD45 + / CD3 + cells were engrafted in all tissues on day + 5 according to cytofluorimetry, immunohistology, and PCR. Lymphocytes ''homed'' to the white pulp T -cell area and to the red pulp; liver localization is prevalently at the periportal area. After GCV ( day + 19 ), cytofluorimetry and immunohistology showed very few CD3 + cells. PCR identified the transgene in 22% tissue samples ( positive only in thymus and spleen ). GvHD did not occur in any
M alignant hematological diseases are usually treated with induction chemotherapy, followed by consolidation therapy, the best of which is allogeneic bone marrow transplantation ( BMT ). Successful disease eradication depends on the conditioning regimen and the Graft -versusLeukemia (GvL ) reaction, i.e., the allogeneic suppression of residual neoplastic cells by donor antihost cytolytic T cells. 1 However, GvL is closely associated with acute and chronic Graft -versus -Host Disease (GvHD ), which is the major cause of morbidity and mortality after allogeneic BMT. 2, 3 Overcoming GvHD while maintaining an effective GvL is the main challenge in eradicating neoplastic clones.
Gene engineering with suicide genes makes target cells sensitive to a chemotherapeutic agent that is not normally toxic. 4 The thymidine kinase gene of the herpes simplex type I virus ( HSV-tk ) is a suitable candidate because it selectively phosphorylates ganciclovir ( GCV ), leading to its incorporation into DNA, thus causing cell death. Consequently, T lymphocytes engineered with HSV-tk gene could be used to trigger a controlled GvL / GvHD reaction, and make repeated infusions of adequate doses of T lymphocytes feasible. 5, 6 We have already shown that phytohemoagglutinin /interleukin -2 ( PHA /IL -2 )-activated T lymphocytes can be successfully transduced with a retroviral vector containing the tk and neomycin resistance (NeoR ) genes. 7 The gene transfer procedures allow for a specific GCV T-cell sensitivity and have no significant effect on lymphocyte subset composition, ability to produce and respond to IL -2, and alloresponsiveness. However, compared with control populations, their clonogenicity, as assessed by limiting dilution analysis, is reduced by 2.9 log. 8 T lymphocytes, which are transduced with the tk gene, are currently being used in clinical studies that infuse donor T lymphocytes with the transplant in order to facilitate engraftment. 9 Donor-transduced T lymphocytes are also used to prevent and treat leukemia relapse after bone marrow transplants. 10 However, no data are available on the homing of transduced T lymphocytes in both animal models and humans. In order to further understand the behavior and fate of tk -transduced T cells, we injected engineered T cells in NOD /SCID mice and monitored them by means of cytofluorimetric analysis, polymerase chain reaction (PCR ), and immunohistological studies. We wanted to determine how transduced cells were distributed in this mouse model and see whether GCV eliminated them. Our results show that genetically modified human lymphocytes colonize the lymphoid organs and the bone marrow. GCV markedly reduces the number of infused lymphocytes but does not fully eliminate them, and the thymus and spleen are the main reservoirs of the residual cells.
Methods

Retroviral vector and packaging cell lines
LSN -tk is a retroviral vector derived from the Moloney murine leukemia virus. This vector contains the HSV-tk gene controlled by the long terminal repeat ( LTR ) promoter, and NeoR gene, transcribed from the early promoter of an internal simian virus 40 ( SV40 ) ( Fig 1) . The GP + envAM12 -derived packaging cell line was obtained as previously reported. 7 Collection, processing, transduction, and selection of donor lymphocytes Lymphocytes were obtained from healthy donors (after informed consent ) by lymphocytopheresis. Mononuclear cells were separated on a Ficoll-Hypaque gradient and monocytes were removed from the mononuclear fraction by adherence in 100 -mm Petri dishes for 2 hours at 378C. Lymphocytes were cultivated in RPMI -1640 medium ( Gibco BRL, Gaithersburg, MD ), supplemented with 10% human AB serum ( Biowhittaker, Walkersville, MD ), penicillin /streptomycin, and L -glutamine and then activated with phytohemagglutinin ( PHA; 2 g/ mL) (Biochron, Berlin, Germany ) and recombinant human IL -2 (100 U /mL; Eurocetus, Amsterdam, the Netherlands ). Infection was performed by using a centrifugation -facilitated protocol as previously described. 7 Briefly, after resuspension in viral supernatant at 1Â10 6 / mL, lymphocytes were centrifuged at 1800 rpm for 45 minutes at 308C, and placed in six -well plates. Polybrene was added (4 g /mL) to the cell suspension. After centrifugation, the viral supernatant was removed and cells were resuspended in complete RPMI and, after incubation for 2 hours at 378C, another centrifugation step was performed. The day after, the entire procedure was repeated.
After transduction, cells were resuspended in a fresh medium for 24 hours and then cultivated with G418 (Gibco BRL ) at a concentration of 0.6 mg / mL for 7 days. During transduction procedures, the donor lymphocyte phenotype was determined by FACS analysis (days 0, + 7, and +14) and the percentage of infected cells was determined by NeoR PCR ( see below ).
In vivo studies
The NOD /SCID mice (Charles River, Lecco, Italy ) were housed two to three in a sterile cage in an air-filtered environment and fed ad libitum with sterile laboratory chow and water supplemented with ciprofloxacin. Mice were conditioned with 3.5 total body irradiation delivered at a dose rate of 30 cGy /min with a 4-MV linear accelerator.
NOD /SCID mice were divided into four groups with nine mice in each group.
Group I. Mice received 80Â10 6 resting T lymphocytes. They were sacrificed on days + 5 (a ) and +19 (b ) after lymphocyte infusion, and samples of peripheral blood, bone marrow, thymus, spleen, and liver were taken for cytofluorimetric analysis with CD3.
Group II. Mice received 80Â10 6 activated T lymphocytes. They were sacrificed on days + 5 (a ) and +19 (b ) after lymphocyte infusion, and samples of peripheral blood, bone marrow, thymus, spleen, and liver were taken for cytofluorimetric analysis with CD3.
Group III. Mice received 80Â10
6 transduced T lymphocytes. They were sacrificed on days + 5 (a ) and + 19 ( b) after lymphocyte infusion, and samples of peripheral blood, bone marrow, thymus, spleen, and liver were taken for cytofluorimetric analysis with CD3. NeoR -based PCR was performed as described above. Immunohistological studies with a polyclonal antihuman CD3 antibody ( DAKO, Glostrup, Denmark ) followed by alkaline phosphatase and monoclonal anti -alkaline phosphatase ( APAAP ) APAAP staining 11 were also performed on spleens and livers.
Group IV. Mice received 80Â10 6 transduced T lymphocytes. They were sacrificed on days + 5 (a ) and +19 (b ) after infusion, i.e., after 14 days of GCV treatment (10 mg /kg daily ). Samples of peripheral blood, bone marrow, thymus, spleen, and liver were taken for cytofluorimetric analysis with CD3. NeoR -based PCR was performed as described above. Immunohistological studies with a polyclonal antihuman CD3 antibody followed by APAAP staining 11 were also performed on spleens and livers. We also tested a different schedule of GCV administration, starting on day +8 ( 10 mg / kg daily) until day +22. Samples of peripheral blood on day + 22 were taken for cytofluorimetric analysis with CD3 and NeoR -based PCR.
Cells were isolated from mouse tissues of all four groups of mice by removing organs, passing them through filters, and washing them twice in phosphate -buffered solution. Erythrocytes were lysed, cells were washed twice, and counted.
One -way analysis of variance was applied to compare peripheral blood CD + cells in the four groups, once at time + 5, and again at time +19. Scheffe's test was used to see in which couple of means the P value was statistically significant. 
Fluorescence -activated cell sorting ( FACS ) analysis
The phenotype of transduced lymphocytes was determined using a panel of mouse monoclonal antibodies ( MoAbs ) directed against the following antigens: CD3, CD4, CD8, CD11, CD16, CD19, CD25 ( Coulter, Hialeah, FL ), HLA -DR (Ylem, Rome, Italy), CD20, and CD56 ( Immunotech, Marseille, France ) using an indirect fluorescence labeling method. Cells were analyzed by Epics XL cytometer (Coulter) on days 0, 7 ( postinfection ), and 14 ( postselection ).
The percentage of CD3 + cells ( Coulter ) in the murine tissues was determined using a direct fluorescence labeling method. Cells were analyzed by Epics XL cytometer ( Coulter ).
PCR analysis
PCR analysis was used to detect the NeoR gene in the transduced cells obtained from murine tissues. A total of 1Â10 6 cells were lysed in 500 L of a buffer containing Tris -HCl 10 mM, KCl 50 mM, MgCl 2 2.5 mM, gelatin 0.1%, NP40 0.45%, Tween 20 0.45%, Proteinase K 100 mg / mL. The extract ( 10 L ) was used for a PCR reaction with the following NeoR primers: 5 0 -GGT GGA GAG GCT ATT CGG CTA TGA -3 0 and 5 0 -TCC TGA TCG ACA AGA CCG GCT TCC -3 0 , as previously reported. 8 b -Actin DNA was amplified with the same protocol and used as internal control for DNA integrity and loading.
DNA was amplified using 34 cycles of incubation at 948C ( 30 seconds ), 558C (30 seconds), and 728C (45 seconds ), followed by a 10 -minute extension at 728C. The amplified fragment was separated by electrophoresis in a 2% agarose gel and visualized by ethidium bromide staining.
PCR analysis was used to detect the tk gene in the transduced cells obtained from murine tissues. A total of 1Â10 6 cells were lysed as above and the extract (10 L ) was used for a PCR reaction with the following tk primers: 5 0 -CTT GAA CCT CCT CGT TCG -3 0 and 5 0 -CCT GGG GAC TTT CCA CAC -3 0 . The fragment was 1.266 bp. b-Actin DNA was amplified with the same protocol and used as internal control for DNA integrity and loading. DNA was amplified using 35 cycles of incubation at 948C ( 45 seconds ), 508C ( 1 minute ), and 728C (1 minute ), followed by a 10 -minute extension at 728C. The amplified fragment was separated by electrophoresis in a 2% agarose gel and visualized by ethidium bromide staining.
Immunohistological studies
For immunohistological studies, murine spleen and liver were removed at sacrifice and fixed into B5 fixative. All tissues were then processed through alcohol dehydration and paraffinization. Tissues were embedded in paraffin and sectioned at 3 m. All slides were incubated with a polyclonal antihuman CD3 antibody followed by APAAP staining.
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Results
Transduction efficiency and characterization of tk lymphocytes
Before G418 selection, transduction efficiency of primary T lymphocytes with LSN -tk retroviral vector was 30 ± 10%, as measured by semiquantitative NeoR -based PCR. Group II ( received 80Â10 6 activated T lymphocytes ). CD3 expression was similar in all tissue samples at the same time points ( Table 1 ). The activation process did not influence engraftment or survival of infused cells. Furthermore, the patterns of cell distribution in the different tissues were maintained in both groups. No GvHD was seen at a cell 
Treatment and monitoring of NOD / SCID mice with transduced T lymphocytes
Group III of NOD /SCID mice received 80Â10 6 tktransduced T lymphocytes with no acute toxic effects. On day +5, the engraftment rate was significantly lower than in groups I and II and persisted until day +19 with no significant differences in the pattern of tissue distribution. A possible explanation of this result may lie in the decrease in clonable lymphocytes after retroviral transduction and G418 selection, as we observed in in vitro studies. 8 No cases of GvHD were found in group III at the cell dosage used. Scheffe's test showed a significant difference (P < .00) in the percentage of CD3 + cells in groups I and II versus groups III and IV on day + 5.
NeoR -based PCR confirmed engraftment on day + 5 in all tissues. The NeoR gene was very evident in peripheral blood, thymus, spleen, and liver and very weak in the bone marrow ( Fig 2, panel A ) .
The tk -based PCR showed the same pattern of distribution of the NeoR gene (Fig 2, panel C ) .
Effect of GCV treatment on tk + circulating cells
The group IV of NOD /SCID mice received 80Â10 6 tk -transduced T lymphocytes and GCV (10 mg / kg/day) for 14 days. After GCV treatment, the percentage of CD3 + cells dropped sharply and very few CD3 + cells were detectable in any tissues (Table 1 ). According to the Scheffe's test, the differences in the number of CD3 + cells between group I or II and groups III and IV (P < .00) and between groups III and IV (P < .056 ) on day + 19 were statistically significant.
NeoR -based PCR showed that the signal had completely disappeared from the bone marrow, liver, and peripheral blood, whereas it persisted in 22% of all tissues ( one positive spleen, one positive thymus ) ( Fig 2, panel B ) . The tk -based PCR confirmed the presence of tk gene at the same time as the NeoR gene was present (Fig 2, panel D ) .
After changing the GCV schedule (GCV was given from days +8 to +22 ), we found a higher number of residual CD3 + cells ( Fig 3) . NeoR -based PCR showed no signal in the peripheral blood when the treatment was initiated on day Cancer Gene Therapy tk lymphocytes into NOD/SCID mice M Di Ianni et al + 5, whereas a positive lane was found in peripheral blood when GCV was started on day + 8.
Immunohistological studies
Immunohistological staining of the spleens confirmed that CD3 + human cells were present on day + 5 (engraftment ) ( Fig 4, upper right panel ) and had almost completely disappeared after GCV treatment (day +19 ) (Fig 4, upper  left panel ) . Human CD3 + lymphocytes ''homed'' to the white pulp T-cell area ( Fig 4, lower right panel ) and also infiltrated the red pulp (Fig 4, lower left panel ) .
Immunohistological staining of the liver showed few CD3 + human cells on day +5 (engraftment ) (Fig 5, lower  panel ) , which almost completely disappeared after GCV treatment ( day +19 ) (Fig 5, upper panel ) . Human CD3 + lymphocytes ''homed'' preferentially to the periportal areas.
Discussion
Knowledge of the distribution and fate of T lymphocytes transduced with the tk gene is of crucial importance when these cells are used in adoptive cellular therapies or in new bone marrow transplant strategies, as is currently being proposed. 9, 10 In the present report, engraftment of the human T lymphocytes in NOD /SCID mice was assessed using freshly engineered T lymphocytes. CD45 + /CD3 + flowcytometric analysis, PCR detection of NeoR gene, and immunohistological staining of mouse tissues (spleen and liver) with antibodies specific for human CD3 antigen showed that engraftment was successful. Confirming other reports, 12 we observed CD3 + T cells engrafted in mouse tissues irrespective of whether they had been activated before transfer or not. However, when we analyzed the engraftment of transduced population in the different tissues, we found that the percentage of CD3 + cells dropped sharply compared with untransduced populations. In our view, this may be linked with the loss of clonogenicity in the transduced selected population as we previously reported in in vitro studies. 8 The variation in the numbers of CD3 + cells recovered from transplanted NOD /SCID mice was also observed by Krams et al 13 using nonactivated human PBMC for xenotransplantation (between 0% and 56% was CD3 + ). Hoffmann -Fezer et al 14 reported that human untransduced T cells in the murine spleens have a perivascular distribution with the CD8 subtype prevailing in the red pulp, and the CD4 in the white pulp region. In our experiments, human CD3 + transduced lymphocytes ''homed'' to the white pulp T-cell area and also infiltrated the red pulp, indicating that the transduction procedure and retroviral integration do not alter the T-lymphocyte homing pattern. We observed that T lymphocytes are localized prevalently at the periportal area of the liver, which is the same homing pattern reported 14 for untransduced T cells.
Xenogenic T cells, when injected into NOD /SCID mice, are reported to engraft with a relatively low overall incidence of GVHD.
14 After infusing transduced cells, we found no histological evidence of GVHD. Several explanations may account for this phenomenon. One hypothesis is that growth of xenogenic cells is not sustained optimally and activation by antigen presenting cells is more marked in the allogeneic host than in the xenogenic host. Furthermore, the cytokine network is less active in the NOD /SCID mouse. Several authors 15, 16 have demonstrated no T-cell functional activity immediately after cells are removed from the animals. This lack of functional activity might be due to the murine microenvironment inhibiting human T-cell response or to the selective survival of T cells that do not recognize the antigens. One might speculate that continuous antigenic stimulus might be necessary to maintain human T-cell function.
NeoR -based PCR analysis showed that very few T lymphocytes persisted after GCV treatment. The HSV-tk gene is reported to be either partially 17 or completely 18 deleted from the resistant HSV-tk -transduced cells. The low incidence of GvHD reported by others in clinical trials 10 might, on the other hand, indicate that these transduced T cells do not, in fact, respond to recipient alloantigens, thus suggesting that in vivo resistance is associated with the activation status of the genetically modified cell. This hypothesis is supported by the well-known cell replication -dependent activity of HSV-tk. 19 Another mechanism that could underlie GCV resistance is the transgene methylation /demethylation status. Our previous study demonstrated how long -term transgene expression in a mouse model could be influenced by the methylation status of the retrovirus, which can be reversed by treatment with a demethylating agent such as 5-azacytidine. 20 Further studies are, however, necessary to address the question definitively.
We also demonstrated that GCV sensitivity of the tk -transduced cells was schedule-dependent. In fact, when GCV treatment was performed on days + 8 to + 22, the number of residual CD3 + cells was higher than in the group treated from days +5 to +19. In a recent study, Drobyski et al 21 reported an increased incidence of GvHD in transgenic mice that underwent matched BMT and tk -transduced cells when GCV treatment was started on day +7 instead of day + 3. In our view, delaying GCV therapy could, on one hand, trigger gene methylation mechanisms and /or transgene deletion and, on the other, recruit accessory cells that Cancer Gene Therapy tk lymphocytes into NOD/SCID mice M Di Ianni et al maintain GvHD even after GCV depletion of the tk T lymphocytes.
In conclusion, this study provides for the first time critical information on the distribution and fate of tk -transduced T lymphocytes in NOD /SCID mice. Neither tk -transduced nor untransduced lymphocytes are associated with acute toxicity, and both cell populations follow the same pattern in circulating and homing into mice tissues. This study also shows that GCV treatment does not always eradicate the transduced T cells and whether the few lymphocytes that escape the GCV treatment are quiescent remains to be established. Interestingly, it is worth noting that some cases of GvHD have been reported in patients receiving tktransduced lymphocytes for leukemia relapse after allogeneic stem cell transplantation. 10 The present observation may throw some light on the biological mechanisms underlying the failure of GCV treatment.
